Background-Bactericidallpermeability-
increasing protein (BPI), a constituent of primary neutrophil granules, is a potent natural antibiotic and an antineutrophil cytoplasm antibody (ANCA) antigen in cases ofvasculitis in which the target antigen is neither myeloperoxidase (MPO) nor proteinase-3 (PR3). Aim-To investigate BPI as a possible target antigen for ANCAs in inflammatory bowel disease. Methods-ANCAs were detected by routine immunofluorescence (IIF) and solid phase enzyme linked immunosorbent assay (ELISA) performed for antibodies to the purified neutrophil granule proteins; MPO, PR3, cathepsin-G, lactoferrin, and BPI in serum samples from 88 patients with inflammatory bowel disease (36 with Crohn's disease, 52 with ulcerative colitis). Thirty patients with bacterial enteritis acted as controls.
Results-Significantly more patients with ulcerative colitis were ANCA positive by IIF (60%) than patients with Crohn's disease (28%) or infectious enteritis (23%) (p<0001). IgG anti-BPI antibodies were present in 29% of patients with ulcerative colitis, 14% of patients with Crohn's disease, and 23% of patients with infectious enteritis, occurring in 44% of those patients with inflammatory bowel disease who were ANCA positive by IIF. Antibodies to other ANCA antigens were rare. The presence of ANCAs was not related to either disease activity or extent; presence of anti-BPI antibodies was significantly related to both a lower serum albumin concentration (p=0O001) and a higher erythrocyte sedimentation rate (p=002) in patients with ulcerative colitis, and to colonic involvement in patients with Crohn's disease (p=001).
Conclusion-BPI is a significant minority target antigen for ANCAs in inflammatory bowel disease that seems related to colonic Crohn's disease and disease activity in ulcerative colitis. Anti-BPI antibodies occur in infectious enteritis. (Gut 1997; 40: 105-109) Keywords: antineutrophil cytoplasm autoantibodies, bactericidal/permeability-increasing protein, ulcerative colitis, Crohn's disease.
The idiopathic inflammatory bowel diseases are among the conditions in which a high proportion of patients exhibit the presence of antineutrophil cytoplasm autoantibodies (ANCAs), the target antigens and pathogenetic importance of which have not yet been characterised.' Recently bactericidal/permeability increasing protein (BPI), a constituent of the primary neutrophil granules, has been characterised as an ANCA antigen in vasculitic patients2 and patients with cystic fibrosis. 3 Stoffell et al have found anti-BPI antibodies in 37% of patients with ulcerative colitis, 23% of patients with Crohn's disease, and 36% of patients with primary sclerosing cholangitis4; however, no attempt was made to correlate these findings with clinical variables.
BPI has high affinity for Gram negative bacterial lipopolysaccharide (LPS), a potent stimulator of monocyte/macrophages and the endothelium that induces cells to express procoagulant activity,5 the leucocyte adhesion molecules E-selectin and ICAM-1,6 and proinflammatory cytokines.7 It has been reported to protect the endothelium from this activation and injury. 8 The aim of this study was to investigate the prevalence and possible clinical relevance of BPI antibodies in inflammatory bowel disease, with reference to type, activity, site, and extent of the disease.
Methods

PATIENTS
Serum samples were collected prospectively from patients with ulcerative colitis (n=52) and Crohn's disease (n=36) under the care of the Royal Free Hospital. Diagnosis of ulcerative colitis was on clinical, radiological, and histological grounds, and that of Crohn's disease on evidence of small bowel involvement or colonic histology showing transmural inflammation or granuloma formation. Serum samples from patients admitted with bacterial enteritis (n=30) acted as controls; blood was taken during the acute phase of their illness and the diagnoses were confirmed by stool or blood cultures.
For patients with inflammatory bowel disease, disease activity was assessed by the Harvey-Bradshaw simple index of Crohn's disease activity,9 the simple clinical colitis activity index,'0 an integrated activity index for ulcerative colitis calculated from clinical and laboratory data,"1 and by the relevant haematological and biochemical markers of haemoglobin, packed cell volume, platelet count, C reactive protein, erythrocyte sedimentation rate, and albumin.'2 Disease site and extent in the patients with inflammatory bowel disease was based on the last endoscopic or radiological investigation before the serum was collected. Serum was stored at -20°C until tested.
Of the 52 cases of ulcerative colitis 17 were men and the median age was 48-7 years (range 21-8-82-2 years). Twelve had either total or extensive disease (colitis distal to the hepatic flexure), 24 had left sided or rectosigmoid disease, and 13 had limited proctitis. Three patients had undergone colectomy, one with ileal pouch formati6n, one with ileorectal anastomosis, and one with terminal ileostomy. Of the 36 patients with Crohn's disease 20 were men and the median age was 37-95 years (range 21-7-82); 16 had colonic involvement.
The median age of the 30 patients with infectious enteritis was 34-4 years (range 20-5-83) and 19 were men. The diagnoses were Campylobacter sp infection in 12, salmonellosis in 11, shigellosis in three (one also having concomitant amoebiasis), enteric fever (Salmonella paratyphi A) in three, and one with Clostridium difficile.
ANCA ASSAYS
Preparation of neutrophil granule proteins Cathepsin-G, PR3, and MPO were purified from fresh buffy coat preparations as described previously.'3 BPI was purified using techniques described by Zhao et al.' Lactoferrin was purchased commercially (Sigma Chemical Co, Poole, Dorset, UK). Each purified protein was assayed for antigenic purity by enzyme linked immunosorbent assay (ELISA) using antibodies specific to the neutrophil granule proteins MPO, PR3, lactoferrin, cathepsin-G, elastase, and BPI as described.2
Solid phase ELISA Antigens were diluted in coating buffer (0-05 M bicarbonate buffer, pH 9-6) to give a final concentration of 1 ,ug/ml, except for BPI, which was diluted in phosphate buffered saline (PBS) to a final concentration of 0-5 5g/ml. All volumes added were 100 RI/well. Microtitre plates (Dynatech Labs Ltd, Billinghurst, England) were coated such that there were two wells containing antigen and two antigen free wells for each sample. Antigen free wells were treated with coating buffer alone for all antigens, except BPI, when PBS alone was used. Incubation was for one hour at 370C for all antigens, except BPI, when plates were left for one hour at room temperature. After washing three times with 0-1% Tween 20 in PBS and drying, serum was added at a dilution of 1:50 in 1% gelatine and 0-1% Tween 20 in PBS (PBSGT20). Plates were incubated for one hour at 37°C followed by repeat washing and addition of alkaline phosphatase conjugated goat antihuman IgG (Stratech Scientific Ltd, Luton, Beds, UK) diluted 1:300 in PBSGT20. Further incubation and washing was followed, finally, by addition of alkaline phosphatase substrate (Sigma Chemicals Ltd, Poole, Dorset, England) diluted to 1 mg/ml in substrate buffer. Plates were read when the optical density at 405 nm of positive sample was greater than 1 0. In all ELISAs the positive serum samples were taken as 100% and the negative samples as 10%: a sample was positive if activity was greater than 16% (mean plus 3 SD from 46 normal blood donors). Positive serum samples were chosen as those with the highest specific antigen binding from the samples referred routinely to the laboratory. All the positive reference patients were ANCA positive by IIF and had systemic vasculitis. (Table II) . In the analysis of markers of disease activity (Table III) 22 The presence of anti-BPI antibodies in this study is associated significantly with colonic involvement in Crohn's disease, and with disease activity as measured by both serum albumin and erythrocyte Results are given as means (SD). Hb=haemoglobin; Plts=platelets; ESR=erythrocyte sedimentation rate; PCV=packed cell volume.
*p<0-02; **p<0-0013. ( 1 3) [3] [4] (1-7) 22 (17) 42-6 (5-2) 3-0 (2 3)
Anti-BPI -(n=31) (1-9) 304 (92) 0 394 (0-052) 2-9 (2-1) 18 
